• Profile
Close

Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer

Head & Neck Mar 10, 2019

Yasumatsu R, et al. - A sum of 41 cases with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) to assess the utility of neutrophil-to-lymphocyte ratio (NLR) kinetics to predict the anticancer impact of nivolumab using pretreatment blood test results. They noticed higher posttreatment NLR as compared to the pretreatment value 76% of subjects with progressive disease within the first 3 months. But, among stable disease or partial response during the follow-up period, they recorded lower posttreatment NLR than the pretreatment value in 91% of cases. Consequently, they suggested monitoring of NLR as it might help in pre-confirming the treatment failure during nivolumab monotherapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay